TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global Nonalcoholic Steatohepatitis (NASH) Market Research Report 2022

Global Nonalcoholic Steatohepatitis (NASH) Market Research Report 2022

  • Category:Life Sciences
  • Published on : 06 November 2022
  • Pages :86
  • Formats:
  • Report Code:SMR-7478713
OfferClick for best price

Best Price: $2320

Nonalcoholic Steatohepatitis NASH Market Size, Share 2022


Market Analysis and Insights: Global Nonalcoholic Steatohepatitis NASH Market

The global Nonalcoholic Steatohepatitis NASH market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Nonalcoholic Steatohepatitis NASH market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Nonalcoholic Steatohepatitis NASH market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Nonalcoholic Steatohepatitis NASH market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Nonalcoholic Steatohepatitis NASH market.

Global Nonalcoholic Steatohepatitis NASH Scope and Market Size

Nonalcoholic Steatohepatitis (NASH) market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Nonalcoholic Steatohepatitis (NASH) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

Obeticholic acid?OCA?

Selonsertib

Segment by Application

Hospital Pharmacy

Online Provider

Retail Pharmacy

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

By Company

AstraZeneca

Arena Pharmaceuticals

GSK

Novo Nordisk

Roche

Vivus

Arisaph Pharmaceuticals

Cempra Pharmaceuticals

Galectin Therapeutics

Galmed Pharmaceuticals

Genfit

Gilead

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Nonalcoholic Steatohepatitis NASH product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Nonalcoholic Steatohepatitis NASH, with price, sales, revenue, and global market share of Nonalcoholic Steatohepatitis NASH from 2019 to 2022.

Chapter 3, the Nonalcoholic Steatohepatitis NASH competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Nonalcoholic Steatohepatitis NASH breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Nonalcoholic Steatohepatitis NASH market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Nonalcoholic Steatohepatitis NASH.

Chapter 13, 14, and 15, to describe Nonalcoholic Steatohepatitis NASH sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 Nonalcoholic Steatohepatitis NASH Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes Report Details
Report Title Global Nonalcoholic Steatohepatitis (NASH) Market Research Report 2022
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2021
Forecast Year 2029
Number of Pages 86 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Obeticholic acid?OCA?
1.2.3 Selonsertib
1.3 Market by Application
1.3.1 Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacy
1.3.3 Online Provider
1.3.4 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Perspective (2017-2028)
2.2 Nonalcoholic Steatohepatitis (NASH) Growth Trends by Region
2.2.1 Nonalcoholic Steatohepatitis (NASH) Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Region (2017-2022)
2.2.3 Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Region (2023-2028)
2.3 Nonalcoholic Steatohepatitis (NASH) Market Dynamics
2.3.1 Nonalcoholic Steatohepatitis (NASH) Industry Trends
2.3.2 Nonalcoholic Steatohepatitis (NASH) Market Drivers
2.3.3 Nonalcoholic Steatohepatitis (NASH) Market Challenges
2.3.4 Nonalcoholic Steatohepatitis (NASH) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nonalcoholic Steatohepatitis (NASH) Players by Revenue
3.1.1 Global Top Nonalcoholic Steatohepatitis (NASH) Players by Revenue (2017-2022)
3.1.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Players (2017-2022)
3.2 Global Nonalcoholic Steatohepatitis (NASH) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Nonalcoholic Steatohepatitis (NASH) Revenue
3.4 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio
3.4.1 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nonalcoholic Steatohepatitis (NASH) Revenue in 2021
3.5 Nonalcoholic Steatohepatitis (NASH) Key Players Head office and Area Served
3.6 Key Players Nonalcoholic Steatohepatitis (NASH) Product Solution and Service
3.7 Date of Enter into Nonalcoholic Steatohepatitis (NASH) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Nonalcoholic Steatohepatitis (NASH) Breakdown Data by Type
4.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Type (2017-2022)
4.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Type (2023-2028)
5 Nonalcoholic Steatohepatitis (NASH) Breakdown Data by Application
5.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Application (2017-2022)
5.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size (2017-2028)
6.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022)
6.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size (2017-2028)
7.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022)
7.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size (2017-2028)
8.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022)
8.3 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size (2017-2028)
9.2 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022)
9.3 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size (2017-2028)
10.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022)
10.3 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Introduction
11.1.4 AstraZeneca Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.1.5 AstraZeneca Recent Development
11.2 Arena Pharmaceuticals
11.2.1 Arena Pharmaceuticals Company Detail
11.2.2 Arena Pharmaceuticals Business Overview
11.2.3 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
11.2.4 Arena Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.2.5 Arena Pharmaceuticals Recent Development
11.3 GSK
11.3.1 GSK Company Detail
11.3.2 GSK Business Overview
11.3.3 GSK Nonalcoholic Steatohepatitis (NASH) Introduction
11.3.4 GSK Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.3.5 GSK Recent Development
11.4 Novo Nordisk
11.4.1 Novo Nordisk Company Detail
11.4.2 Novo Nordisk Business Overview
11.4.3 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Introduction
11.4.4 Novo Nordisk Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.4.5 Novo Nordisk Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Nonalcoholic Steatohepatitis (NASH) Introduction
11.5.4 Roche Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.5.5 Roche Recent Development
11.6 Vivus
11.6.1 Vivus Company Detail
11.6.2 Vivus Business Overview
11.6.3 Vivus Nonalcoholic Steatohepatitis (NASH) Introduction
11.6.4 Vivus Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.6.5 Vivus Recent Development
11.7 Arisaph Pharmaceuticals
11.7.1 Arisaph Pharmaceuticals Company Detail
11.7.2 Arisaph Pharmaceuticals Business Overview
11.7.3 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
11.7.4 Arisaph Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.7.5 Arisaph Pharmaceuticals Recent Development
11.8 Cempra Pharmaceuticals
11.8.1 Cempra Pharmaceuticals Company Detail
11.8.2 Cempra Pharmaceuticals Business Overview
11.8.3 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
11.8.4 Cempra Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.8.5 Cempra Pharmaceuticals Recent Development
11.9 Galectin Therapeutics
11.9.1 Galectin Therapeutics Company Detail
11.9.2 Galectin Therapeutics Business Overview
11.9.3 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Introduction
11.9.4 Galectin Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.9.5 Galectin Therapeutics Recent Development
11.10 Galmed Pharmaceuticals
11.10.1 Galmed Pharmaceuticals Company Detail
11.10.2 Galmed Pharmaceuticals Business Overview
11.10.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
11.10.4 Galmed Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.10.5 Galmed Pharmaceuticals Recent Development
11.11 Genfit
11.11.1 Genfit Company Detail
11.11.2 Genfit Business Overview
11.11.3 Genfit Nonalcoholic Steatohepatitis (NASH) Introduction
11.11.4 Genfit Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.11.5 Genfit Recent Development
11.12 Gilead
11.12.1 Gilead Company Detail
11.12.2 Gilead Business Overview
11.12.3 Gilead Nonalcoholic Steatohepatitis (NASH) Introduction
11.12.4 Gilead Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
11.12.5 Gilead Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Obeticholic acid?OCA?
Table 3. Key Players of Selonsertib
Table 4. Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 5. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2017-2022) & (US$ Million)
Table 7. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Region (2017-2022)
Table 8. Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 9. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Region (2023-2028)
Table 10. Nonalcoholic Steatohepatitis (NASH) Market Trends
Table 11. Nonalcoholic Steatohepatitis (NASH) Market Drivers
Table 12. Nonalcoholic Steatohepatitis (NASH) Market Challenges
Table 13. Nonalcoholic Steatohepatitis (NASH) Market Restraints
Table 14. Global Nonalcoholic Steatohepatitis (NASH) Revenue by Players (2017-2022) & (US$ Million)
Table 15. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Players (2017-2022)
Table 16. Global Top Nonalcoholic Steatohepatitis (NASH) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nonalcoholic Steatohepatitis (NASH) as of 2021)
Table 17. Ranking of Global Top Nonalcoholic Steatohepatitis (NASH) Companies by Revenue (US$ Million) in 2021
Table 18. Global 5 Largest Players Market Share by Nonalcoholic Steatohepatitis (NASH) Revenue (CR5 and HHI) & (2017-2022)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Nonalcoholic Steatohepatitis (NASH) Product Solution and Service
Table 21. Date of Enter into Nonalcoholic Steatohepatitis (NASH) Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2017-2022) & (US$ Million)
Table 24. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Type (2017-2022)
Table 25. Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 26. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Type (2023-2028)
Table 27. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2017-2022) & (US$ Million)
Table 28. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Application (2017-2022)
Table 29. Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 30. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Application (2023-2028)
Table 31. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022) & (US$ Million)
Table 32. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028) & (US$ Million)
Table 33. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022) & (US$ Million)
Table 34. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028) & (US$ Million)
Table 35. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2017-2022) & (US$ Million)
Table 36. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2023-2028) & (US$ Million)
Table 37. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022) & (US$ Million)
Table 38. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028) & (US$ Million)
Table 39. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022) & (US$ Million)
Table 40. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028) & (US$ Million)
Table 41. AstraZeneca Company Detail
Table 42. AstraZeneca Business Overview
Table 43. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Product
Table 44. AstraZeneca Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
Table 45. AstraZeneca Recent Development
Table 46. Arena Pharmaceuticals Company Detail
Table 47. Arena Pharmaceuticals Business Overview
Table 48. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product
Table 49. Arena Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
Table 50. Arena Pharmaceuticals Recent Development
Table 51. GSK Company Detail
Table 52. GSK Business Overview
Table 53. GSK Nonalcoholic Steatohepatitis (NASH) Product
Table 54. GSK Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
Table 55. GSK Recent Development
Table 56. Novo Nordisk Company Detail
Table 57. Novo Nordisk Business Overview
Table 58. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product
Table 59. Novo Nordisk Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
Table 60. Novo Nordisk Recent Development
Table 61. Roche Company Detail
Table 62. Roche Business Overview
Table 63. Roche Nonalcoholic Steatohepatitis (NASH) Product
Table 64. Roche Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
Table 65. Roche Recent Development
Table 66. Vivus Company Detail
Table 67. Vivus Business Overview
Table 68. Vivus Nonalcoholic Steatohepatitis (NASH) Product
Table 69. Vivus Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
Table 70. Vivus Recent Development
Table 71. Arisaph Pharmaceuticals Company Detail
Table 72. Arisaph Pharmaceuticals Business Overview
Table 73. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product
Table 74. Arisaph Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
Table 75. Arisaph Pharmaceuticals Recent Development
Table 76. Cempra Pharmaceuticals Company Detail
Table 77. Cempra Pharmaceuticals Business Overview
Table 78. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product
Table 79. Cempra Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
Table 80. Cempra Pharmaceuticals Recent Development
Table 81. Galectin Therapeutics Company Detail
Table 82. Galectin Therapeutics Business Overview
Table 83. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Product
Table 84. Galectin Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
Table 85. Galectin Therapeutics Recent Development
Table 86. Galmed Pharmaceuticals Company Detail
Table 87. Galmed Pharmaceuticals Business Overview
Table 88. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product
Table 89. Galmed Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
Table 90. Galmed Pharmaceuticals Recent Development
Table 91. Genfit Company Detail
Table 92. Genfit Business Overview
Table 93. Genfit Nonalcoholic Steatohepatitis (NASH)Product
Table 94. Genfit Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
Table 95. Genfit Recent Development
Table 96. Gilead Company Detail
Table 97. Gilead Business Overview
Table 98. Gilead Nonalcoholic Steatohepatitis (NASH)Product
Table 99. Gilead Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
Table 100. Gilead Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Type: 2021 VS 2028
Figure 2. Obeticholic acid?OCA? Features
Figure 3. Selonsertib Features
Figure 4. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application in 2021 & 2028
Figure 5. Hospital Pharmacy Case Studies
Figure 6. Online Provider Case Studies
Figure 7. Retail Pharmacy Case Studies
Figure 8. Nonalcoholic Steatohepatitis (NASH) Report Years Considered
Figure 9. Global Nonalcoholic Steatohepatitis (NASH) Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 10. Global Nonalcoholic Steatohepatitis (NASH) Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Region: 2021 VS 2028
Figure 12. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Players in 2021
Figure 13. Global Top Nonalcoholic Steatohepatitis (NASH) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nonalcoholic Steatohepatitis (NASH) as of 2021)
Figure 14. The Top 10 and 5 Players Market Share by Nonalcoholic Steatohepatitis (NASH) Revenue in 2021
Figure 15. North America Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 16. North America Nonalcoholic Steatohepatitis (NASH) Market Share by Country (2017-2028)
Figure 17. United States Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 18. Canada Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. Europe Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Europe Nonalcoholic Steatohepatitis (NASH) Market Share by Country (2017-2028)
Figure 21. Germany Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. France Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. U.K. Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Italy Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Russia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Nordic Countries Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Share by Region (2017-2028)
Figure 29. China Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Japan Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. South Korea Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. India Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Australia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Latin America Nonalcoholic Steatohepatitis (NASH) Market Share by Country (2017-2028)
Figure 37. Mexico Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Brazil Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Share by Country (2017-2028)
Figure 41. Turkey Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. AstraZeneca Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
Figure 44. Arena Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
Figure 45. GSK Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
Figure 46. Novo Nordisk Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
Figure 47. Roche Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
Figure 48. Vivus Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
Figure 49. Arisaph Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
Figure 50. Cempra Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
Figure 51. Galectin Therapeutics Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
Figure 52. Galmed Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
Figure 53. Genfit Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
Figure 54. Gilead Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount